Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 115 |
Referral date | 01 December 2007 |
Topic area |
|
Provisional Schedule
Closing date for invited submissions / evidence submission: | TBC |
1st appraisal committee meeting: | TBC |
2nd appraisal committee meeting | TBC |
Project Team
Communications manager: | Sarita Tamber |
Executive Lead: | Gillian Leng |
Project manager: | Bijal Joshi |
Technical Lead: | Scott Goulden |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
10 August 2009 |
Further to the Scoping Workshop, lapatinib for the first-line treatment of metastatic hormone-sensitive breast cancer has been temporarily suspended. Following discussion of the comments received during the scoping exercises/workshop, we are liaising with the Department of Health for confirmation that lapatinib is appraised alongside trastuzumab, in a Multiple Technology Appraisal. When further details are available, the website will be updated. |
For further information on our processes and methods, please see our CHTE processes and methods manual